TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Tonix Pharma ( (TNXP) ) has issued an announcement.
On November 18, 2025, Tonix Pharmaceuticals Holding Corp. announced that its Board of Directors approved an increase to its share repurchase program. The company may now repurchase up to an additional $25 million in value of its outstanding common stock, raising the total authorized shares under the program to $35 million.
The most recent analyst rating on (TNXP) stock is a Sell with a $17.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Underperform.
Tonix Pharma’s overall stock score is primarily impacted by its financial performance and valuation challenges. The company faces significant profitability and cash flow issues, which are reflected in its negative P/E ratio. Technical analysis indicates a bearish trend, with the stock trading below key moving averages and approaching oversold conditions. These factors collectively contribute to a low overall stock score.
To see Spark’s full report on TNXP stock, click here.
More about Tonix Pharma
Average Trading Volume: 1,009,507
Technical Sentiment Signal: Sell
Current Market Cap: $187.2M
For an in-depth examination of TNXP stock, go to TipRanks’ Overview page.